Integrated network pharmacology and AlphaFold modeling reveal ESR1 as a key target of Huanglian Jiedu decoction for ameliorating sepsis-induced coagulopathy - PubMed
7 hours ago
- #Sepsis
- #Coagulopathy
- #Traditional Chinese Medicine
- Huanglian Jiedu Decoction (HLJDD) is a traditional Chinese medicine with antibacterial, anti-inflammatory, and coagulation-improving properties.
- The study focuses on HLJDD's efficacy in treating sepsis-induced coagulopathy (SIC) using network pharmacology and AlphaFold modeling.
- HLJDD was shown to improve coagulation dysfunction, reduce inflammation, and mitigate organ damage in septic rats.
- Key targets identified include ESR1, IL-6, and CXCL8, with quercetin as a major active compound in HLJDD.
- Quercetin binds to ESR1, potentially enhancing its interaction with estrogen response elements (EREs) to alleviate SIC.
- HLJDD's mechanism involves upregulating ESR1 to suppress inflammation and microthrombosis, offering therapeutic potential for SIC.